Differential effects of estrogen-dependent transactivation vs. transrepression by the estrogen receptor on invasiveness of HER2 overexpressing breast cancer cells

被引:4
|
作者
Patki, Mugdha [1 ,2 ]
Salazar, Marcela d'Alincourt [2 ,3 ]
Trumbly, Robert [2 ]
Ratnam, Manohar [1 ]
机构
[1] Barbara Ann Karmanos Canc Inst, Dept Oncol, Detroit, MI 48201 USA
[2] Univ Med Ctr, Dept Biochem & Canc Biol, Toledo, OH 43614 USA
[3] City Hope Natl Med Ctr, Beckman Res Inst, Div Translat Res, Duarte, CA 91010 USA
关键词
Estrogen receptor; Tamoxifen; Anti-estrogens; Invasiveness; Breast cancer; HER2; TRANSCRIPTION FACTOR; TAMOXIFEN; ALPHA; MECHANISMS; INVASION; ACTIVATION; RESISTANCE; PHENOTYPE; MOTILITY; OUTCOMES;
D O I
10.1016/j.bbrc.2015.01.004
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Estrogen (E-2) supports breast cancer cell growth but suppresses invasiveness and both actions are antagonized by anti-estrogens. As a consequence, anti-estrogen treatment may increase the invasive potential of estrogen receptor (ER)+ tumor cell sub-populations that are endocrine resistant due to HER2 amplification. Either transactivation or transrepression by E-2/ER could lead to both up- and down-regulation of many genes. Inhibition of the transactivation function of ER is adequate to inhibit E-2-dependent growth. However, the impact of inhibiting E-2-dependent transactivation vs. transrepression by ER on regulation of invasiveness by E-2 is less clear. Here we dissect the roles of ER-mediated transactivation and transrepression in the regulation of invasiveness of ER+/HER2+ breast cancer cells by E-2. Knocking down the general ER co-activators CBP and p300 prevented activation by E-2 of its classical target genes but did not interfere with the ability of E-2 to repress its direct target genes known to support invasiveness and tumor progression; there was also no effect on invasiveness or the ability of E-2 to regulate invasiveness. On the other hand, overexpression of a co-repressor binding site mutant of ER (L372R) prevented E-2-dependent transrepression but not transactivation. The mutant ER abrogated the ability of E-2 to suppress invasiveness. E-2 can partially down-regulate HER2 but knocking down HER2 below E-2-regulated levels did not affect invasiveness or the ability of E-2 to regulate invasiveness, although it did inhibit growth. Therefore, in ER+/HER2+ cells, the E-2-dependent transrepression by ER rather than its transactivation function is critical for regulation of invasiveness and this is independent of HER2 regulation by E-2. The findings suggest that selective inhibitors of transactivation by ER may be more beneficial in reducing tumor progression than conventional anti-estrogens that also antagonize E-2-dependent transrepression. (C) 2015 Elsevier Inc. All rights reserved.
引用
收藏
页码:404 / 411
页数:8
相关论文
共 50 条
  • [41] Microarray-Based Determination of Estrogen Receptor, Progesterone Receptor, and HER2 Receptor Status in Breast Cancer
    Roepman, Paul
    Horlings, Hugo M.
    Krijgsman, Oscar
    Kok, Marleen
    Bueno-de-Mesquita, Jolien M.
    Bender, Richard
    Linn, Sabine C.
    Glas, Annuska M.
    van de Vijver, Marc J.
    CLINICAL CANCER RESEARCH, 2009, 15 (22) : 7003 - 7011
  • [42] HER2 mRNA Levels, Estrogen Receptor Activity and Susceptibility to Trastuzumab in Primary Breast Cancer
    Triulzi, Tiziana
    Regondi, Viola
    Venturelli, Elisabetta
    Gasparini, Patrizia
    Ghirelli, Cristina
    Groppelli, Jessica
    Di Modica, Martina
    Bianchi, Francesca
    De Cecco, Loris
    Sfondrini, Lucia
    Tagliabue, Elda
    CANCERS, 2022, 14 (22)
  • [43] In vitro inhibition of proliferation of estrogen-dependent and estrogen independent human breast cancer cells treated with carotenoids or retinoids
    Prakash, P
    Russell, RM
    Krinsky, NI
    JOURNAL OF NUTRITION, 2001, 131 (05): : 1574 - 1580
  • [44] HER2 positivity in patients with estrogen receptor (ER) positive breast cancer: Is it really prognostic?
    Batra, Atul
    Kumar, Akash
    BREAST, 2021, 55 : 136 - 136
  • [45] Aberrant Splicing of Estrogen Receptor, HER2, and CD44 Genes in Breast Cancer
    Inoue, Kazushi
    Fry, Elizabeth A.
    GENETICS & EPIGENETICS, 2015, 7 : 19 - 32
  • [46] Estrogen receptor codon 594 and HER2 codon 655 polymorphisms and breast cancer risk
    Akisik, E
    Dalay, N
    EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2004, 76 (03) : 260 - 263
  • [47] Mechanisms of resistance to estrogen receptor modulators in ER+/HER2− advanced breast cancer
    Jin Zhang
    Qianying Wang
    Qing Wang
    Jiangran Cao
    Jiafu Sun
    Zhengmao Zhu
    Cellular and Molecular Life Sciences, 2020, 77 : 559 - 572
  • [48] Melatonin inhibits estrogen receptor transactivation and cAMP levels in breast cancer cells
    Kiefer, T
    Ram, PT
    Yuan, L
    Hill, SM
    BREAST CANCER RESEARCH AND TREATMENT, 2002, 71 (01) : 37 - 45
  • [49] Effects of chlorpyrifos on growth of estrogen-dependent human breast cancer cell line
    Ventura, C.
    Nunez, M. A.
    Gaido, V.
    Martinel Lamas, D.
    Randi, A. S.
    Venturino, A.
    Rivera, E. S.
    Cocca, C. M.
    TOXICOLOGY LETTERS, 2011, 205 : S80 - S80
  • [50] Melatonin inhibits estrogen receptor transactivation and cAMP levels in breast cancer cells
    T. Kiefer
    P. T. Ram
    L. Yuan
    S. M. Hill
    Breast Cancer Research and Treatment, 2002, 71 : 37 - 45